3,4-diamino-3-cyclobutene-1,2-dione derivatives as potassium channel openers

Abstract

The present invention is directed to novel 3,4-diamino-3-cyclobutene-1,2-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders related to potassium channel.

1 - 7 . (canceled) 
   
   
       8 . A method of treating a disorder related to ion channels, comprising administering, to a subject in need thereof, a therapeutically effective amount of the compound of formula (I) 
     
       
         
         
             
             
         
       
     
     wherein
 n is an integer from 0 to 2; 
 R 1  is selected from the group consisting of cycloalkyl aryl and heteroaryl; 
 wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen hydroxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano, nitro, C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkyl and halogen substituted C 1-4 alkoxy; 
 
     or a pharmaceutically acceptable salt thereof. 
   
   
       9 . The method of  claim 8 , wherein the ion channel is a potassium ion channel. 
   
   
       10 . The method of  claim 9 , wherein the ion channel is an ATP-sensitive potassium ion channel. 
   
   
       11 . The method of  claim 8 , wherein the disorder related to ion channels is selected from the group consisting of urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowel syndrome, airway hyperactivity, epilepsy, stroke, Alzheimer's disease, Parkinson's disease, myocardial injury, coronary artery disease, hair loss and baldness. 
   
   
       12 . The method of  claim 8 , wherein the disorder related to ion channels is selected from the group consisting of urinary incontinence and overactive bladder. 
   
   
       13 . A method of treating a disorder selected from the group consisting of urinary incontinence, overactive bladder, hypertension, erectile dysfunction, female sexual disorders, dysmenorrhea, irritable bowel syndrome, airway hyperactivity, epilepsy, stroke, Alzheimer's disease, Parkinson's disease, myocardial injury, coronary artery disease, hair loss and baldness, comprising administering, to a subject in need thereof, a therapeutically effective amount of the composition of formula (I) 
     
       
         
         
             
             
         
       
     
     wherein
 n is an integer from 0 to 2; 
 R 1  is selected from the group consisting of cycloalkyl, aryl and heteroaryl; 
 wherein the aryl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, hydroxy, amino, C 1-4 alkylamino, di(C 1-4 alkyl)amino, cyano, nitro, C 1-4 alkyl, C 1-4 alkoxy, halogen substituted C 1-4 alkyl and halogen substituted C 1-4 alkoxy; 
 
     or a pharmaceutically acceptable salt thereof.